Dong Xiaopei, Lu Ning, Tong Zhongsheng, Shi Yehui
Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, People's Republic of China.
Onco Targets Ther. 2021 Feb 10;14:929-936. doi: 10.2147/OTT.S267022. eCollection 2021.
Recently, programmed cell death 1(PD-1) inhibitors have shown a significant curative effect in the treatment of most solid cancers and some hematological malignancies. The effects of PD-1 inhibitors in recurrent head and neck squamous cell carcinoma (HNSCC) have also been confirmed. However, there is a lack of reliable clinical evidence to confirm the safety and efficacy of PD-1 inhibitors in patients after allogeneic hematopoietic stem cell transplantation, especially when the patient has a second primary cancer. Generally, graft-versus-host disease (GVHD) is unpredictable among these patients. Here we report the case of a patient who successfully used nivolumab without any GVHD or other immune-related adverse events for HNSCC after allogeneic bone marrow transplantation because of the Philadelphia chromosome-positive T cell acute lymphoblastic leukemia.
最近，程序性细胞死亡蛋白1（PD-1）抑制剂在大多数实体癌和一些血液系统恶性肿瘤的治疗中显示出显著疗效。PD-1抑制剂在复发性头颈部鳞状细胞癌（HNSCC）中的作用也已得到证实。然而，缺乏可靠的临床证据来证实PD-1抑制剂在异基因造血干细胞移植患者中的安全性和有效性，尤其是当患者患有第二原发性癌症时。一般来说，这些患者中移植物抗宿主病（GVHD）是不可预测的。在此，我们报告一例因费城染色体阳性T细胞急性淋巴细胞白血病接受异基因骨髓移植后成功使用纳武单抗治疗HNSCC且未发生任何GVHD或其他免疫相关不良事件的患者病例。
